Most and least shorted mid- to mega-cap healthcare stocks at the end of September
Seeking Alpha News (Fri, 2-Oct 10:00 AM ET)
Business Wire (Mon, 21-Sep 9:14 AM ET)
The Market Just Told You Which Layer Of AI Biology It Is Paying For
Globe Newswire (Thu, 3-Sep 2:10 PM ET)
Globe Newswire (Wed, 5-Aug 6:30 AM ET)
Recursion to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 4-Aug 8:00 AM ET)
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
Globe Newswire (Fri, 31-Jul 4:30 PM ET)
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
Globe Newswire (Wed, 29-Jul 8:30 AM ET)
Market Chameleon (Mon, 8-Dec 2:58 AM ET)
Recursion Highlights Expansive AI-Driven Approach at Key Healthcare Investor Conferences
Market Chameleon (Tue, 4-Nov 3:37 AM ET)
Recursion Sets Date for Q3 2025 Results—Key Details and What Investors Should Watch
Market Chameleon (Tue, 28-Oct 5:11 AM ET)
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Recursion Pharmaceuticals - Class A trades on the NASDAQ stock market under the symbol RXRX.
As of October 2, 2026, RXRX stock price climbed to $4.12 with 18,103,784 million shares trading.
RXRX has a beta of 2.36, meaning it tends to be more sensitive to market movements. RXRX has a correlation of 0.22 to the broad based SPY ETF.
RXRX has a market cap of $2.21 billion. This is considered a Mid Cap stock.
Last quarter Recursion Pharmaceuticals - Class A reported $8 million in Revenue and -$.25 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.01.
In the last 3 years, RXRX traded as high as $15.74 and as low as $2.77.
The top ETF exchange traded funds that RXRX belongs to (by Net Assets): ARKK, ARKE, XBI, ARKG, IWM.
RXRX has underperformed the market in the last year with a return of -19.2%, while SPY returned +16.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in RXRX shares. However, RXRX has outperformed the market in the last 3 month and 2 week periods, returning +12.3% and +16.4%, while SPY returned +3.5% and +1.4%, respectively. This indicates RXRX has been having a stronger performance recently.
RXRX support price is $3.86 and resistance is $4.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RXRX shares will trade within this expected range on the day.
